Preclinical evaluation of a third-generation absorbable antibacterial envelope

IF 5.6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Heart rhythm Pub Date : 2023-05-01 DOI:10.1016/j.hrthm.2023.01.018
Charles J. Love MD , Ibrahim Hanna MD , George Thomas MD , Arnold J. Greenspon MD , Melissa Christie MS , Jonathan Goodman PhD , Matthew Christopherson BA , Vasanthi Balaji PhD , Shira Skulsky MS , Matthew Sanders , Carrie Bauer BS , William Schindeldecker AA , Nicole Kirchhof DVM , M. Rizwan Sohail MD
{"title":"Preclinical evaluation of a third-generation absorbable antibacterial envelope","authors":"Charles J. Love MD ,&nbsp;Ibrahim Hanna MD ,&nbsp;George Thomas MD ,&nbsp;Arnold J. Greenspon MD ,&nbsp;Melissa Christie MS ,&nbsp;Jonathan Goodman PhD ,&nbsp;Matthew Christopherson BA ,&nbsp;Vasanthi Balaji PhD ,&nbsp;Shira Skulsky MS ,&nbsp;Matthew Sanders ,&nbsp;Carrie Bauer BS ,&nbsp;William Schindeldecker AA ,&nbsp;Nicole Kirchhof DVM ,&nbsp;M. Rizwan Sohail MD","doi":"10.1016/j.hrthm.2023.01.018","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The TYRX (Medtronic) absorbable antibacterial envelope has been shown to stabilize implantable cardiac devices and reduce infection. A third-generation envelope was developed to reduce surface roughness with a redesigned multifilament mesh and enhanced form factor but identical polymer coating and antibiotic concentrations as the currently available second-generation envelope.</p></div><div><h3>Objective</h3><p>The purpose of this study was to compare drug elution, bacterial challenge efficacy, stabilization, and absorption of second- vs third-generation envelopes.</p></div><div><h3>Methods</h3><p>Antibiotic elution was assessed <em>in vitro</em> and <em>in vivo.</em><span> For efficacy against gram-positive/gram-negative bacteria, 40 rabbits underwent device insertions with or without third-generation envelopes. For stabilization (migration, rotation), 5 sheep were implanted with 6 devices each in second- or third-generation envelopes. Prespecified acceptance criteria were &lt;83-mm migration and &lt;90° rotation. Absorption was assessed via gross pathology.</span></p></div><div><h3>Results</h3><p>Elution curves were equivalent (similarity factors ≥50 per Food and Drug Administration guidance). Third-generation envelopes eluted antibiotics above minimal inhibitory concentration (MIC) <em>in vivo</em> at 2 hours postimplant through 7 days, consistent with second-generation envelopes. Bacterial challenge showed reductions (<em>P</em> &lt;.05) in infection with second- and third-generation envelopes. Device migration was 5.5 ± 3.5 mm (third-generation) vs 9. 9 ±7.9 mm (second-generation) (<em>P</em> &lt;.05). Device rotation was 18.9° ± 11.4° (third-generation) vs 17.6° ± 15.1° (second-generation) and did not differ (<em>P</em> = .79). Gross pathology confirmed the absence of luminal mesh remainders and no differences in peridevice fibrosis at 9 or 12 weeks.</p></div><div><h3>Conclusion</h3><p>The third-generation TYRX absorbable antibacterial envelope demonstrated equivalent preclinical performance to the second-generation envelope. Antibiotic elution curves were similar, elution was above MIC for 7 days, infections were reduced compared to no envelope, and acceptance criteria for migration, rotation, and absorption were met.</p></div>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":"20 5","pages":"Pages 737-743"},"PeriodicalIF":5.6000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart rhythm","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1547527123001005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The TYRX (Medtronic) absorbable antibacterial envelope has been shown to stabilize implantable cardiac devices and reduce infection. A third-generation envelope was developed to reduce surface roughness with a redesigned multifilament mesh and enhanced form factor but identical polymer coating and antibiotic concentrations as the currently available second-generation envelope.

Objective

The purpose of this study was to compare drug elution, bacterial challenge efficacy, stabilization, and absorption of second- vs third-generation envelopes.

Methods

Antibiotic elution was assessed in vitro and in vivo. For efficacy against gram-positive/gram-negative bacteria, 40 rabbits underwent device insertions with or without third-generation envelopes. For stabilization (migration, rotation), 5 sheep were implanted with 6 devices each in second- or third-generation envelopes. Prespecified acceptance criteria were <83-mm migration and <90° rotation. Absorption was assessed via gross pathology.

Results

Elution curves were equivalent (similarity factors ≥50 per Food and Drug Administration guidance). Third-generation envelopes eluted antibiotics above minimal inhibitory concentration (MIC) in vivo at 2 hours postimplant through 7 days, consistent with second-generation envelopes. Bacterial challenge showed reductions (P <.05) in infection with second- and third-generation envelopes. Device migration was 5.5 ± 3.5 mm (third-generation) vs 9. 9 ±7.9 mm (second-generation) (P <.05). Device rotation was 18.9° ± 11.4° (third-generation) vs 17.6° ± 15.1° (second-generation) and did not differ (P = .79). Gross pathology confirmed the absence of luminal mesh remainders and no differences in peridevice fibrosis at 9 or 12 weeks.

Conclusion

The third-generation TYRX absorbable antibacterial envelope demonstrated equivalent preclinical performance to the second-generation envelope. Antibiotic elution curves were similar, elution was above MIC for 7 days, infections were reduced compared to no envelope, and acceptance criteria for migration, rotation, and absorption were met.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
第三代可吸收抗菌膜的临床前评价
美敦力(tyx)可吸收抗菌包膜已被证明可以稳定植入式心脏装置并减少感染。第三代包膜通过重新设计的多丝网格和增强的外形因素来降低表面粗糙度,但与目前可用的第二代包膜相同的聚合物涂层和抗生素浓度。目的比较第二代包膜和第三代包膜的药物洗脱、细菌攻毒效果、稳定性和吸收率。方法体外、体内对抗生素洗脱进行评价。为了对革兰氏阳性/革兰氏阴性细菌的疗效,40只兔子接受了有或没有第三代包膜的装置插入。为了稳定(迁移,旋转),5只羊被植入了6个装置,每个装置在第二代或第三代包膜中。预先设定的验收标准是偏移<83毫米和旋转<90°。通过大体病理评估吸收。结果溶液曲线等效(相似因子≥50,美国食品药品监督管理局指南)。第三代包膜在植入后2小时至7天内洗脱超过最低抑制浓度(MIC)的抗生素,与第二代包膜一致。细菌攻击显示第二代和第三代包膜感染的减少(P < 0.05)。设备迁移为5.5±3.5 mm(第三代)vs 9。9±7.9 mm(第二代)(P < 0.05)。器械旋转为18.9°±11.4°(第三代)vs 17.6°±15.1°(第二代),无差异(P = 0.79)。大体病理证实,在9周或12周时,没有腔内补片残留物,并且在装置周围纤维化方面没有差异。结论第三代TYRX可吸收抗菌膜与第二代抗菌膜具有相当的临床前性能。抗生素洗脱曲线相似,洗脱在MIC以上持续7天,与无包膜相比感染减少,并且符合迁移、旋转和吸收的接受标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Heart rhythm
Heart rhythm 医学-心血管系统
CiteScore
10.50
自引率
5.50%
发文量
1465
审稿时长
24 days
期刊介绍: HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability. HeartRhythm integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community. The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards.
期刊最新文献
Cardiac resynchronization therapy (CRT) nonresponders in the contemporary era: A state-of-the-art review. The electromechanical window for arrhythmia-risk assessment. Analysis of electrogram peak frequency during ventricular tachycardia ablation: Insights into human tridimensional ventricular tachycardia circuits. Letter to the Editor-Revisiting the prognostic role of SCN5A in Brugada syndrome. Reply to the Editor- Revisiting the prognostic role of SCN5A in Brugada syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1